These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 33431401)

  • 1. A Community Partnership to Improve Access to Buprenorphine in a Homeless Population.
    Leo P; Gastala N; Fleurimont J; Messmer S; Maes P; Richardson J; Neeb C; Stackhouse N; Koruba S; Watson DP
    Ann Fam Med; 2021; 19(1):85. PubMed ID: 33431401
    [No Abstract]   [Full Text] [Related]  

  • 2. Mobile, Community-Based Buprenorphine Treatment for Veterans Experiencing Homelessness With Opioid Use Disorder: A Pilot, Feasibility Study.
    Iheanacho T; Payne K; Tsai J
    Am J Addict; 2020 Nov; 29(6):485-491. PubMed ID: 32367557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management.
    Mehtani NJ; Ristau JT; Snyder H; Surlyn C; Eveland J; Smith-Bernardin S; Knight KR
    Subst Abus; 2021; 42(2):205-212. PubMed ID: 33684331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TIME TO REVISIT UNEVEN POLICY IN THE UNITED STATES FOR MEDICATION FOR OPIOID USE DISORDER DURING COVID-19.
    Pena E; Ahmed S
    Addiction; 2020 Oct; 115(10):1978-1979. PubMed ID: 32447795
    [No Abstract]   [Full Text] [Related]  

  • 5. Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic.
    Peckham AM; Ball J; Colvard MD; Dadiomov D; Hill LG; Nichols SD; Tallian K; Ventricelli DJ; Tran TH
    Am J Health Syst Pharm; 2021 Mar; 78(7):613-618. PubMed ID: 33411894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-Barrier Buprenorphine Treatment for People Experiencing Homelessness.
    Gibson CL; Lo E
    Psychiatr Serv; 2023 Jan; 74(1):104. PubMed ID: 36254451
    [No Abstract]   [Full Text] [Related]  

  • 7. A health crisis within a health crisis: Opioid access in the COVID-19 pandemic.
    Narayan A; Balkrishnan R
    Subst Abus; 2021; 42(2):148-152. PubMed ID: 33849399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low Threshold Telemedicine-based Opioid Treatment for Criminal Justice Involved Adults During the COVID-19 Pandemic: A Case Report.
    Flavin L; Tofighi B; Krawczyk N; Schatz D; McNeely J; Butner J
    J Addict Med; 2022 Jan-Feb 01; 16(1):e59-e61. PubMed ID: 35120069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilization of long-acting injectable monthly depot buprenorphine for opioid use disorder (OUD) in Kentucky, before and after COVID-19 related buprenorphine access policy changes.
    Hammerslag LR; Talbert J; Slavova S; Lei F; Freeman PR; Marks KR; Fanucchi LC; Walsh SL; Lofwall MR
    J Subst Use Addict Treat; 2024 Sep; 164():209391. PubMed ID: 38740189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.
    Cochran G; Bruneau J; Cox N; Gordon AJ
    Subst Abus; 2020; 41(3):269-274. PubMed ID: 32697171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder.
    Weintraub E; Seneviratne C; Anane J; Coble K; Magidson J; Kattakuzhy S; Greenblatt A; Welsh C; Pappas A; Ross TL; Belcher AM
    JAMA Netw Open; 2021 Aug; 4(8):e2118487. PubMed ID: 34448869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low Barrier Tele-Buprenorphine in the Time of COVID-19: A Case Report.
    Harris M; Johnson S; Mackin S; Saitz R; Walley AY; Taylor JL
    J Addict Med; 2020; 14(4):e136-e138. PubMed ID: 32433364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buprenorphine Opioid Treatment During the COVID-19 Pandemic.
    Luigi M; Luo M; Maes EJP
    JAMA Intern Med; 2021 Aug; 181(8):1135. PubMed ID: 33843962
    [No Abstract]   [Full Text] [Related]  

  • 15. Access to treatment for opioid use disorders: Medical student preparation.
    McCance-Katz EF; George P; Scott NA; Dollase R; Tunkel AR; McDonald J
    Am J Addict; 2017 Jun; 26(4):316-318. PubMed ID: 28394437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine Opioid Treatment During the COVID-19 Pandemic-Reply.
    Nguyen TD; Saloner B; Stein BD
    JAMA Intern Med; 2021 Aug; 181(8):1135-1136. PubMed ID: 33843947
    [No Abstract]   [Full Text] [Related]  

  • 17. Commentary on Schmidt et al.: Informed patient preference and prioritizing access to medications for opioid use disorder for pregnant individuals.
    Morgan JR; Leech AA
    Addiction; 2024 Jun; 119(6):1123-1124. PubMed ID: 38570825
    [No Abstract]   [Full Text] [Related]  

  • 18. The case for a medication first approach to the treatment of opioid use disorder.
    Winograd RP; Presnall N; Stringfellow E; Wood C; Horn P; Duello A; Green L; Rudder T
    Am J Drug Alcohol Abuse; 2019; 45(4):333-340. PubMed ID: 31084515
    [No Abstract]   [Full Text] [Related]  

  • 19. A Mobile Buprenorphine Treatment Program for Homeless Patients With Opioid Use Disorder.
    Buzza C; Elser A; Seal J
    Psychiatr Serv; 2019 Jul; 70(7):635-636. PubMed ID: 31258036
    [No Abstract]   [Full Text] [Related]  

  • 20. Payer strategies to ensure access to care for individuals with opioid use disorder during COVID-19.
    Bachireddy C; Terplan M
    Am J Manag Care; 2021 Mar; 27(3):91-92. PubMed ID: 33720664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.